Diagnostic Accuracy of a Combined Analysis of Cerebrospinal Fluid t-PrP, t-tau, p-tau, and Aβ42 in the Differential Diagnosis of Creutzfeldt-Jakob Disease from Alzheimer's Disease with Emphasis on Atypical Disease Variants

Journal of Alzheimer's Disease

Volumn 55, Issue 4, 2017, Pages 1471-1480

  Abu Rumeileh, Samir ^a   Lattanzio, Francesca ^a   Stanzani Maserati, Michelangelo ^b   Rizzi, Romana ^c   Capellari, Sabina ^a,b   Parchi, Piero ^a,b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b BELLARIA HOSPITAL   (Italy)

^c S MARIA NUOVA HOSPITAL   (Italy)

Author keywords

Alzheimer's disease; amyloid ; biomarker; cerebrospinal fluid; Creutzfeldt Jakob disease; prion protein; tau protein

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; PRION PROTEIN; TAU PROTEIN; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); AMYLOID PRECURSOR PROTEIN; PEPTIDE FRAGMENT;

ADULT; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; CREUTZFELDT JAKOB DISEASE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TASK PERFORMANCE; AGED; DIAGNOSTIC IMAGING; DIFFUSION WEIGHTED IMAGING; ELECTROENCEPHALOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PHOSPHORYLATION; PRION;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; CREUTZFELDT-JAKOB SYNDROME; DIAGNOSIS, DIFFERENTIAL; DIFFUSION MAGNETIC RESONANCE IMAGING; ELECTROENCEPHALOGRAPHY; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PHOSPHORYLATION; PRIONS; TAU PROTEINS;

EID: 85007251555     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-160740     Document Type: Article

References (43)

1. Parchi P, Giese A, Capellari S, Brown P, Schulz-Schaeffer W, Windl O, Zerr I, Budka H, Kopp N, Piccardo P, Poser S, Rojiani A, Streichemberger N, Julien J, Vital C, Ghetti B, Gambetti P, Kretzschmar H (1999) Classification of sporadic Creutzfeldt-Jakob disease based on molecular and phenotypic analysis of 300 subjects. Ann Neurol 46, 224-233.
2. Parchi P, Saverioni D (2012) Molecular pathology, classification, and diagnosis of sporadic human prion disease variants. Folia Neuropathol 50, 20-45.
3. Carcaillon L, Peres K, Pere JJ, Helmer C, Orgogozo JM, Dartigues JF (2007) Fast cognitive decline at the time of dementia diagnosis: A major prognostic factor for survival in the community. Dement Geriatr Cogn Disord 23, 439-445.
4. Reinwald S, Westner IM, Niedermaier N (2004) Rapidly progressive Alzheimer's disease mimicking Creutzfeldt-Jakob disease. J Neurol 251, 1020-1022.
5. Schmidt C, Haïk S, Satoh K, Rábano A, Martinez-Martin P, Roeber S, Brandel JP, Calero-Lara M, de Pedro-Cuesta J, Laplanche JL, Hauw JJ, Kretzschmar H, Zerr I (2012) Rapidly progressive Alzheimer's disease: A multicenter update. J Alzheimers Dis 30, 751-756.
6. Schmidt C, Wolff M, Weitz M, Bartlau T, Korth C, Zerr I (2011) Rapidly progressive Alzheimer disease. Arch Neurol 68, 1124-1130.
7. Zerr I, Kallenberg K, Summers DM, Romero C, Taratuto A, Heinemann U, Breithaupt M, Varges D, Meissner B, Ladogana A, Schuur M, Haik S, Collins SJ, Jansen GH, Stokin GB, Pimentel J, Hewer E, Collie D, Smith P, Roberts H, Brandel JP, van Duijn C, Pocchiari M, Begue C, Cras P, Will RG, Sanchez-Juan P (2009) Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease. Brain 132(Pt 10), 2659-2668.
8. Parchi P, Capellari S (2013) Prion disease: Diagnostic value of cerebrospinal fluid markers. Nat Rev Neurol 9, 10-1.
9. Henriksen K, O'Bryant SE, Hampel H, Trojanowski JQ, Montine TJ, Jeromin A, Blennow K, Lönneborg A, Wyss-Coray T, Soares H, Bazenet C, Sjögren M, Hu W, Lovestone S, Karsdal MA, Weiner MW, Blood-Based Biomarker Interest Group (2014) The future of blood-based biomarkers for Alzheimer's disease. Alzheimers Dement 10, 115-131.
10. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR Jr, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M, Wagster MV, Phelps CH (2011) Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7, 280-292.
11. Huang N, Marie SK, Livramento JA, Chammas R, Nitrini R (2003) 14-3-3 protein in the CSF of patients with rapidly progressive dementia. Neurology 61, 354-357.
12. Jayaratnam S, Khoo AK, Basic D (2008) Rapidly progressive Alzheimer's disease and elevated 14-3-3 proteins in cerebrospinal fluid. Age Ageing 37, 467-469.
13. Kester MI, van der Vlies AE, Blankenstein MA, Pijnenburg YA, van Elk EJ, Scheltens P, van der Flier WM (2009) CSF biomarkers predict rate of cognitive decline in Alzheimer disease. Neurology 73, 1353-1358.
14. Koric L, Felician O, Guedj E, Hubert AM, Mancini J, Boucraut J, Ceccaldi M (2010) Could clinical profile influence CSF biomarkers in early-onset Alzheimer disease? Alzheimer Dis Assoc Disord 24, 278-283.
15. Mahmoudi R, Manckoundia P, Morrone I, Lang PO, Dramé M, Novella JL (2010) Atypical case of Alzheimer's disease mimicking Creutzfeldt-Jakob disease: Interest of cerebrospinal fluid biomarkers in the differential diagnosis. J Am Geriatr Soc 58, 1821-1823.
16. Snider BJ, Fagan AM, Roe C, Shah AR, Grant EA, Xiong C, Morris JC, Holtzman DM (2009) Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type. Arch Neurol 66, 638-645.
17. Stoeck K, Sanchez-Juan P, Gawinecka J, Green A, Ladogana A, Pocchiari M, Sanchez-Valle R, Mitrova E, Sklaviadis T, Kulczycki J, Slivarichova D, Saiz A, Calero M, Knight R, Aguzzi A, Laplanche JL, Peoc'h K, Schelzke G, Karch A, van Duijn CM, Zerr I (2012) Cerebrospinal fluid biomarker supported diagnosis of Creutzfeldt-Jakob disease and rapid dementias: A longitudinal multicentre study over 10 years. Brain 135(Pt 10), 3051-3061.
18. Wallin AK, Blennow K, Zetterberg H, Londos E, Minthon L, Hansson O (2010) CSF biomarkers predict a more malignant outcome in Alzheimer disease. Neurology 74, 1531-1537.
19. Castellani RJ, Colucci M, Xie Z, Zou W, Li C, Parchi P, Capellari S, Pastore M, Rahbar MH, Chen SG, Gambetti P (2004) Sensitivity of 14-3-3 protein test varies in subtypes of sporadic Creutzfeldt-Jakob disease. Neurology 63, 436-442.
20. Sanchez-Juan P, Green A, Ladogana A, Cuadrado-Corrales N, Sáanchez-Valle R, Mitrováa E, Stoeck K, Sklaviadis T, Kulczycki J, Hess K, Bodemer M, Slivarichová D, Saiz A, Calero M, Ingrosso L, Knight R, Janssens AC, van Duijn CM, Zerr I (2006) CSF tests in the differential diagnosis of Creutzfeldt-Jakob disease. Neurology 67, 637-643.
21. Zanusso G, Fiorini M, Ferrari S, Gajofatto A, Cagnin A, Galassi A, Richelli S, Monaco S (2011) Cerebrospinal fluid markers in sporadic Creutzfeldt-Jakob disease. Int J Mol Sci 12, 6281-6292.
22. Van Everbroeck B, Green AJ, Pals P, Martin JJ, Cras P (1999) Decreased levels of amyloid-beta 1-42 in cerebrospinal fluid of Creutzfeldt-Jakob disease patients. J Alzheimers Dis 1, 419-424.
23. Otto M, Esselmann H, Schulz-Shaeffer W, Neumann M, Schröter A, Ratzka P, Cepek L, Zerr I, Steinacker P, Windl O, Kornhuber J, Kretzschmar HA, Poser S, Wiltfang J (2000) Decreased beta-amyloid1-42 in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Neurology 54, 1099-1102.
24. Kapaki E, Kilidireas K, Paraskevas GP, Michalopoulou M, Patsouris E (2001) Highly increased CSF tau protein and decreased beta-amyloid (1-42) in sporadic CJD: A discrimination from Alzheimer's disease? J Neurol Neurosurg Psychiatry 71, 401-403.
25. Wiltfang J, Esselmann H, Smirnov A, Bibl M, Cepek L, Steinacker P, Mollenhauer B, Buerger K, Hampel H, Paul S, Neumann M, Maler M, Zerr I, Kornhuber J, Kretzschmar HA, Poser S, Otto M (2003) Beta-amyloid peptides in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Ann Neurol 54, 263-267.
26. Mollenhauer B, Esselmann H, Roeber S, Schulz-Schaeffer WJ, Trenkwalder C, Bibl M, Steinacker P, Kretzschmar HA, Wiltfang J, Otto M (2011) Different CSF β-amyloid processing in Alzheimer's and Creutzfeldt-Jakob disease. J Neural Transm (Vienna) 118, 691-697.
27. Varges D, Jung K, Gawinecka J, Heinemann U, Schmitz M, von Ahsen N, Krasnianski A, Armstrong VW, Zerr I (2011) Amyloid-β 1-42 levels are modified by apolipoprotein E ϵ4 in Creutzfeldt-Jakob disease in a similar manner as in Alzheimer's disease. J Alzheimers Dis 23, 717-726.
28. Blennow K, Johansson A, Zetterberg H (2005) Diagnostic value of 14-3-3beta immunoblot and T-tau/P-tau ratio in clinically suspected Creutzfeldt-Jakob disease. Int J Mol Med 16, 1147-1149.
29. Dorey A, Tholance Y, Vighetto A, Perret-Liaudet A, Lachman I, Krolak-Salmon P, Wagner U, Struyfs H, De Deyn PP, El-Moualij B, Zorzi W, Meyronet D, Streichenberger N, Engelborghs S, Kovacs GG, Quadrio I (2015) Association of cerebrospinal fluid prion protein levels and the distinction between Alzheimer disease and Creutzfeldt-Jakob disease. JAMA Neurol 72, 267-275.
30. Skillbäck T, Rosén C, Asztely F, Mattsson N, Blennow K, Zetterberg H (2014) Diagnostic performance of cerebrospinal fluid total tau and phosphorylated tau in Creutzfeldt-Jakob disease: Results from the Swedish Mortality Registry. JAMA Neurol 71, 476-483.
31. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH (2011) The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7, 263-269.
32. Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW, Duyckaerts C, Frosch MP, Masliah E, Mirra SS, Nelson PT, Schneider JA, Thal DR, Trojanowski JQ, Vinters HV, Hyman BT, National Institute on Aging, Alzheimer's Association (2012) National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: A practical approach. Acta Neuropathol 123, 1-11.
33. Jansen C, Parchi P, Capellari S, Ibrahim-Verbaas CA, Schuur M, Strammiello R, Corrado P, Bishop MT, van Gool WA, Verbeek MM, Baas F, van Saane W, Spliet WG, Jansen GH, van Duijn CM, Rozemuller AJ (2012) Human prion diseases in the Netherlands (1998-2009): Clinical, genetic and molecular aspects. PLoS One 7, e36333.
34. Parchi P, de Boni L, Saverioni D, Cohen ML, Ferrer I, Gambetti P, Gelpi E, Giaccone G, Hauw JJ, Höftberger R, Ironside JW, Jansen C, Kovacs GG, Rozemuller A, Seilhean D, Tagliavini F, Giese A, Kretzschmar HA (2012) Consensus classification of human prion disease histotypes allows reliable identification of molecular subtypes: An inter-rater study among surveillance centres in Europe and USA. Acta Neuropathol 124, 517-529.
35. Parchi P, Notari S, Weber P, Schimmel H, Budka H, Ferrer I, Haik S, Hauw JJ, Head MW, Ironside JW, Limido L, Rodriguez A, Ströbel T, Tagliavini F, Kretzschmar HA (2009) Inter-laboratory assessment of PrPSc typing in Creutzfeldt-Jakob disease: A western blot study within the Neuro Prion Consortium. Brain Pathol 19, 384-391.
36. Baiardi S, Capellari S, Ladogana A, Strumia S, Santangelo M, Pocchiari M, Parchi P (2015) Revisiting the Heidenhain variant of Creutzfeldt-Jakob disease: Evidence for prion type variability influencing clinical course and laboratory findings. J Alzheimers Dis 50, 465-476.
37. Llorens F, Ansoleaga B, Garcia-Esparcia P, Zafar S, Grau-Rivera O, López-González I, Blanco R, Carmona M, Yagüe J, Nos C, Del Río JA, Gelpí E, Zerr I, Ferrer I (2013) PrP mRNA and protein expression in brain and PrP (c) in CSF in Creutzfeldt-Jakob disease MM1 and VV2. Prion 7, 383-393.
38. Schmitz M, Lüllmann K, Zafar S, Ebert E, Wohlhage M, Oikonomou P, Schlomm M, Mitrova E, Beekes M, Zerr I (2014) Association of prion protein genotype and scrapie prion protein type with cellular prion protein charge isoform profiles in cerebrospinal fluid of humans with sporadic or familial prion diseases. Neurobiol Aging 35, 1177-1188.
39. Torres M, Cartier L, Matamala JM, Hernández N, Woehlbier U, Hetz C (2012) Altered prion protein expression pattern in CSF as a biomarker for Creutzfeldt-Jakob disease. PLoS One 7, e36159.
40. Meyne F, Gloeckner SF, Ciesielczyk B, Heinemann U, Krasnianski A, Meissner B, Zerr I (2009) Total prion protein levels in the cerebrospinal fluid are reduced in patients with various neurological disorders. J Alzheimers Dis 17, 863-873.
41. Struyfs H, Niemantsverdriet E, Goossens J, Fransen E, Martin JJ, De Deyn PP, Engelborghs S (2015) Cerebrospinal fluid P-Tau181P: Biomarker for improved differential dementia diagnosis. Front Neurol 6, 138.
42. Ghoshal N, Cali I, Perrin RJ, Josephson SA, Sun N, Gambetti P, Morris JC (2009) Codistribution of amyloid beta plaques and spongiform degeneration in familial Creutzfeldt-Jakob disease with the E200K-129M haplotype. Arch Neurol 66, 1240-1246.
43. Laurén J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM (2009) Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature 457, 1128-1132.